Smithkline Beecham Corporation

Glaxosmithkline LLC

Nycomed Austria Gmbh

Other

Affinium Pharmaceuticals, Inc.

Nycomed Pharma as

Smithkline Beecham Corportion

Dirk Andries Heerding

Pradip Kumar Bhatnagar

Peter Kremminger

Franz Rovenszky

Michael Hartmann

Johann Hiebl

Mark Andrew Seefeld

Meagan B Rouse

James Francis Callahan

Kenneth Allen Newlander

Jerry Leroy Adams

William Henry Miller

Dashyant Dhanak

William Edward Bondinell

Dennis Shinji Yamashita

Jack Dale Leber

James Martin Samanen

Jeffrey Michael Axten

Stuart Paul Romeril

Jun Tang

Seth Wilson Grant

Stephen M LoCastro

Kenneth C McNulty

Calvin O Manning

Tammy J Clark

Igor Safonov

Jesus Rual Medina

Peter Martin Fischer

Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Inhibitors of AkT activity

The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R, and Rare defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Chemical compounds

Inhibitors of Akt activity

Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.

Deuterated benzene sulfonamide thiazole compounds

Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors

Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Thrombopoietin mimetics

Disubstituted imidazoles useful in the treatment of bacterial infections

Vitronectin receptor antagonists

Novel disubstituted imidazoles are disclosed which are useful in the treatment of bacterial infections, particularly through the inhibition of FAB I.

The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.

Hemoregulatory compounds

Growing community of inventors

Malvern, PA, United States of America

Dirk Andries Heerding